Introduction  

The Gene Therapy Market size is estimated at USD 9.74 billion in 2025, and is expected to reach USD 24.34 billion by 2030, at a CAGR of 20.11% during the forecast period (2025-2030), reflecting a robust CAGR of over 20% during this period. This growth is driven by increasing regulatory approvals for gene therapy products, substantial investments from biopharma and private-equity sectors, and rapid advancements in vector engineering and delivery platforms. North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region due to rising clinical trials and supportive policy frameworks. Hospitals and clinics dominate end-user adoption, while the expanding scope of indications from rare metabolic disorders to oncology and neurology continues to stimulate market expansion. The growing confidence in clinical efficacy and the widening of reimbursement pathways are making gene therapies more accessible, despite the challenges posed by high costs and stringent safety-monitoring requirements. 

Key Trends  

Regulatory Approvals Driving Market Growth 

The gene therapy market is witnessing significant growth due to a steady stream of regulatory approvals, which highlight both the clinical and commercial viability of these therapies. In 2024 alone, nine cell and gene therapy products received approvals, demonstrating increased market readiness and shorter development timelines. Regulatory initiatives such as the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and Europe’s PRIME scheme are accelerating approvals and encouraging investment in innovative therapies. 

Technological Advances in Gene Therapy 

Technological innovations are playing a crucial role in expanding the potential of gene therapies. Advances in vector engineering and in-vivo editing platforms are improving targeting accuracy and reducing immune responses.  

Expansion of Manufacturing Infrastructure 

The growth of viral-vector and non-viral manufacturing infrastructure is another pivotal factor supporting market expansion. Large-scale investments in advanced production facilities are helping to overcome historical supply-chain limitations.  

Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights: 

https://www.mordorintelligence.com/ja/industry-reports/gene-therapy-market?utm_source=emailwire 

 Market Segmentation 

 The gene therapy market can be segmented across several dimensions to better understand demand dynamics and growth potential. Key segments include: 

By Vector Type 

• Adeno Virus Vector 

• Adeno-associated Virus Vector 

• Lentiviral Vector 

• Retroviral Vector 

• Herpes Virus Vector 

• Other Vector Types 

By Indication 

• Oncology 

• Rare Metabolic Disorders 

• Ophthalmology 

• Neurology / CNS 

• Cardiovascular and Musculoskeletal 

• Other Indications 

By Delivery Mode 

• In Vivo Gene Delivery 

• Ex Vivo Gene Delivery 

By End User 

• Hospitals and Clinics 

• Specialty Treatment / Infusion Centers 

• Academic and Research Institutes 

By Geography 

• North America 

• South America 

• Europe 

• Middle east&Africa 

• Asia pacific 

Key Players 

The gene therapy market is highly competitive, involving biotech firms, pharmaceutical companies, and specialized developers.
Key players invest in research, clinical trials, and manufacturing to strengthen pipelines and meet diverse therapeutic needs.
Partnerships, mergers, and acquisitions help expand capabilities, global reach, and production efficiency.
Focus is shifting toward rare and chronic diseases, with combination therapies explored to improve outcomes and access. 

• Gilead Sciences, Inc. 

• Amgen Inc. 

• Novartis AG 

• bluebird bio Inc. 

• Biogen Inc. 

Conclusion: 

 The outlook for the gene therapy market remains highly positive, driven by regulatory support, scientific innovation, and expanding infrastructure. With increasing approvals for novel therapies and a growing pipeline of advanced vectors and delivery technologies, the gene therapy market is set to experience substantial growth in the coming years. North America and Asia-Pacific will continue to dominate market dynamics, providing a diversified base for clinical adoption and commercial success. Ongoing investments and collaborative efforts within the industry will likely reduce cost barriers and enhance treatment accessibility, further strengthening the gene therapy market. 

Industry related Reports: 

Adeno-Associated Virus (AAV) CDMO Market : The Adeno-Associated Virus (AAV) CDMO market report is analyzed across multiple dimensions, including service type, serotype, manufacturing scale, application, end user, and geography. Service types covered include process development, GMP drug-substance manufacturing, and other related services. The report also examines various AAV serotypes such as AAV2, AAV5, and others, alongside different manufacturing scales, including pre-clinical and clinical production. Key applications include gene therapy, ex-vivo cell therapy, and vaccines, while the end-user segment encompasses biotech start-ups, large pharmaceutical companies, and more. The market forecasts for all segments are presented in terms of value (USD). 

Cell And Gene Therapy Market : The Cell and Gene Therapy Market report provides a comprehensive analysis of the industry, segmenting it by therapy type—including cell therapy and gene therapy—by application, such as dermatology, musculoskeletal, oncology, immunology, cardiology, neurology, and others, and by end user, including hospitals, clinics, and others. The report also covers geographic regions, including North America, Europe, Asia Pacific, the Middle East and Africa, and South America, offering five years of historical data along with five-year market forecasts. 

Cell And Gene Therapy Manufacturing Services Market : The cell and gene therapy manufacturing services market is projected to grow from USD 8.0 billion in 2025 to USD 17.18 billion by 2030, at a CAGR of 16.5%. This growth reflects the industry’s transition from experimental treatments to commercially viable therapies, requiring manufacturers to combine pharmaceutical-level reliability with the flexibility needed for living medicines. Regulatory approvals are accelerating capacity demands, prompting companies to advance investment timelines by two to three years compared with traditional biologics. 

About Mordor Intelligence: 

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. 

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. 

For any inquiries or to access the full report, please contact: 

media@mordorintelligence.com
https://www.mordorintelligence.com/